TB-500 is a name used in research-market peptide listings associated with thymosin beta-4. A market name alone does not identify the exact sequence or formulation studied in a paper.
Also referenced as: TB 500 · thymosin beta-4 research.
Check the studied molecule, formulation, and route before transferring a result to a different product.
Research source & evidence
The effect of thymosin treatment of venous ulcers
Annals of the New York Academy of Sciences, 2010 · Phase 2 placebo-controlled human study
Tested topical full-length thymosin beta-4 for venous ulcers and reports a possible healing signal at one concentration.
What this does not establish
Full-length topical thymosin beta-4 is not the same as products sold as TB-500.
TB-500 questions
What is TB-500?
TB-500 is a research-market peptide name associated with thymosin beta-4. The label alone does not establish that a product matches the full-length molecule used in the linked clinical study.
What does the thymosin beta-4 paper study?
The linked phase 2 study investigated topical full-length thymosin beta-4 in people with venous ulcers. It reported a possible healing signal at one studied concentration, within that specific setting.
Is TB-500 the same as full-length thymosin beta-4?
Do not assume equivalence. The paper studied full-length topical thymosin beta-4; products marketed as TB-500 may not match that molecule or formulation.
Does the venous-ulcer trial establish TB-500 safety?
No. A study of a particular topical formulation and population cannot establish the safety or efficacy of every product sold under another name.
Source transparency
AI-assisted research summary based on the linked publication. This is not an independent systematic review or medical review. No named clinical reviewer or independent product verification is claimed. Publication year is the source’s year, not a promise that the evidence is current or complete.
No active affiliate links. Directory listings are not endorsements; research headlines are not clinical evidence.